Factor V Leiden | Italy| PDF | PPT| Case Reports | Symptoms | Treatment

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Factor V Leiden

  • Factor V Leiden

    Factor V Leiden is a mutation of one of the clotting factors in the blood called factor V. This mutation can increase your chance of developing abnormal blood clots (thrombophilia), usually in veins. In this disorder, the Leiden variant of factor V cannot be inactivated by the anticoagulant protein activated protein C, so clotting is encouraged.

    Symptoms: Symptoms of factor v leiden include Pain,significant swelling, Redness and warmth. The first indication that you have the disorder may be the development of a blood clot (thrombosis).

  • Factor V Leiden

    Diagnosis: Two types of tests are performed they are: Activated protein C resistance test: Your blood sample may be tested to determine whether your blood is resistant to activated protein C, one of the anti-clotting proteins that help control factor V. This is known as an activated protein C (APC) resistance assay. If your blood is resistant to activated protein C, you likely have a mutation in the factor V gene. Genetic test: A genetic test is done to determine whether you have a factor V gene mutation. It may also be used to confirm the results of the APC resistance test or to determine whether you've inherited one or two copies of the gene mutation.

  • Factor V Leiden

    Treament: Bleeding complications are the most serious side effect of these medications, but that risk appears to be lower with these drugs than with warfarin: Dabigatran (Pradaxa) Rivaroxaban (Xarelto) Apixaban (Eliquis). Epidemology: Factor V Leiden can act also as concurrent risk factor in individuals with deficiency of natural inhibitors or mild hyperhomocysteinemia. So far, screening for the mutation in individuals with no history of thrombosis is recommended only for relatives of proband patients identified as carriers; the available data do not justify indiscriminate screening before risk situations such as oral contraceptives intake, pregnancy, or high-risk surgery

Expert PPTs
Speaker PPTs

High Impact List of Articles

Conference Proceedings